[1] |
XUE Tian, SHENG Dong, YAN Wanhui, JIANG Xiangnan, LI Huan’ge, LI Xiaoqiu.
Prognostic factors of follicular lymphoma
[J]. China Oncology, 2020, 30(5): 388-393.
|
[2] |
LI Yuan , GU Wenxian , ZHOU Xiaoli , GENG Xiang , SUN Yangyang .
Clinicopathological observation and prognostic analysis of pure mucinous breast carcinoma with micropapillary pattern
[J]. China Oncology, 2020, 30(11): 897-904.
|
[3] |
SUN Yangyang,GENG Xiang,ZHOU Xiaoli,WANG Gengfang,GU Wenxian,ZHANG Xudong .
Clinicopathologic observation and prognostic factor analysis of primary gastric diffuse large B-cell lymphoma
[J]. China Oncology, 2019, 29(9): 715-722.
|
[4] |
LI Wencheng, WANG Xiaoshen.
The selection and application of platinum drugs in the treatment of head and neck squamous cell carcinomas
[J]. China Oncology, 2019, 29(4): 300-306.
|
[5] |
ZHANG Lei, DONG Yunwei, HU Shenbao, et al.
The impact of American Cancer Joint Committee Revised Thyroid Cancer Staging System (8th edition)on staging of papillary thyroid carcinoma
[J]. China Oncology, 2018, 28(7): 491-496.
|
[6] |
SUN Xin, GUO Wei, YANG Rongli, et al.
Outcomes and prognostic factors of high-grade soft tissue sarcoma: experience at a single institution
[J]. China Oncology, 2018, 28(3): 210-215.
|
[7] |
YUAN Yuan, SHEN Zan.
Retrospective analysis of clinical differences and prognostic factors in 32 patients with maxillofacial osteosarcoma
[J]. China Oncology, 2018, 28(2): 134-139.
|
[8] |
WANG Xiaoshen, HU Chaosu.
Anti-EGFR monoclonal antibodies combined with other modalities in treatment of head and neck squamous cell carcinoma
[J]. China Oncology, 2018, 28(12): 881-887.
|
[9] |
GUO Ye.
The immunotherapy for head and neck cancer
[J]. China Oncology, 2017, 27(6): 459-462.
|
[10] |
SONG Yang, LIU Liyang, LI Fenghu, et al.
Expression of HER-2 in 720 cases of breast cancer patients in Guizhou province and retrospective analysis of anti-HER-2 treatment
[J]. China Oncology, 2017, 27(11): 884-889.
|
[11] |
LV Bo, CHEN Yun, LI Yunhai, et al.
Outcomes and clinical prognostic factors for elderly patients with esophageal squamous cell carcinoma treated after definitive chemoradiotherapy
[J]. China Oncology, 2015, 25(3): 217-221.
|
[12] |
LI Jian, YE Ding-wei, YAO Xu-dong, ZHANG Shi-lin, DAI Bo, ZHANG Hai-liang, SHEN Yi-jun, ZHU Yao, SHI Guo-hai, ZHU Yi-ping, MA Chun-guang, QIN Xiaojian, LIN Guo-wen, XIAO Wen-jun.
The value of preoperative platelet to lymphocyte ratio in predicting of clinical stage and prognosis in upper tract urothelial carcinoma
[J]. China Oncology, 2013, 23(6): 457-461.
|
[13] |
GAO Jie, ZHANG Hua, ZHAO Hua-rong, MAO Rui, XIAO Lei, AI Si-ke-er, WEN Hao, BAO Yong-xing.
Analysis of prognosis and influencing factors of 246 Uyghur patients with primary hepatic carcinoma in Xinjiang region
[J]. China Oncology, 2013, 23(5): 362-369.
|
[14] |
GUO Ye.
The progress of targeted therapy in locally advanced head and neck squamous cell carcinomas
[J]. China Oncology, 2013, 23(12): 949-953.
|